Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285801 | 12528580 | 1 | I | 20160620 | 20160705 | 20160705 | EXP | JP-HQ SPECIALTY-JP-2016INT000427 | INTERCHEM | SAKAI H, MATSUDA M, KADOKURA G, KATSUMATA N.. ACUTE HYPERURICEMIA AND KIDNEY INJURY AFTER THREE CYCLES OF DOSE-DENSE CHEMOTHERAPY FOR RETROPERITONEAL CHORIOCARCINOMA -- A CASE REPORT.. GAN TO KAGAKU RYOHO.. 2016;43 (2):263-6 | 32.00 | YR | M | Y | 0.00000 | 20160705 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285801 | 12528580 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | 120 MG/M2, DAY 1-5 | 18057 | 120 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | 100 MG/M2, DAY 1 | 18057 | 100 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 3 | SS | PACLITAXEL. | PACLITAXEL | 1 | 175 MG/M2, DAY 1M | 0 | 175 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 4 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | 130 MG/M2, DAY 10 | 0 | 130 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 5 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | 30 MG/M2, DAY 1 | 0 | 30 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 6 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | 25 MG/M2, DAY 10-14; CONTINUOUS INFUSION | 0 | 25 | MG/M**2 | |||||||||
| 125285801 | 12528580 | 7 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | 100 MG/M2, DAY 1-5 | 0 | 100 | MG/M**2 | INFUSION | ||||||||
| 125285801 | 12528580 | 8 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | 2 MG/M2, DAY 10, 12, 14 | 0 | 2 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125285801 | 12528580 | 1 | Choriocarcinoma |
| 125285801 | 12528580 | 3 | Choriocarcinoma |
| 125285801 | 12528580 | 4 | Choriocarcinoma |
| 125285801 | 12528580 | 5 | Choriocarcinoma |
| 125285801 | 12528580 | 7 | Choriocarcinoma |
| 125285801 | 12528580 | 8 | Choriocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125285801 | 12528580 | OT |
| 125285801 | 12528580 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125285801 | 12528580 | Decreased appetite | |
| 125285801 | 12528580 | Hyperuricaemia | |
| 125285801 | 12528580 | Malaise | |
| 125285801 | 12528580 | Renal injury | |
| 125285801 | 12528580 | Tumour lysis syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |